This dynamic new report from Medtech Insight includes analyses of products, current/forecast markets, competitors, and opportunities in the U.S. market for pain management products. Product areas covered by the scope of this report include pain management pharmaceuticals (e.g., nonprescription analgesics and anesthetics including systemic and topical formulations, as well as prescription analgesics and anesthetics including prescription NSAIDs, opioid analgesics, opioid/nonopioid combination analgesics, antimigraine analgesics, adjuvant analgesics, and general/regional/local anesthetics) and pain management devices (e.g., electrical stimulators including TENS systems and neurostimulators, as well as analgesia infusion pumps including implantable and external models).
During the forecast period covered by this report, the combined U.S. market for pain management products is projected to increase from $36.4 billion in 2013 to $44.7 billion in the year 2018. Pain management pharmaceuticals account for more than 92% of total sales, with pain management devices accounting for the remaining 8% of sales.
EXECUTIVE SUMMARY i. Pain Management Pharmaceuticals a. Nonprescription Analgesics and Anesthetics i. Nonprescription Systemic Analgesics ii. Nonprescription Topical Analgesics iii. Market Forecast b. Prescription Analgesics and Anesthetics i. Prescription Non-Steroidal Anti-Inflammatory Drugs ii. Opioid Analgesics iii. Opioid/Nonopioid Combination Analgesics iv. Antimigraine Analgesics v. Adjuvant Analgesics vi. General, Regional, and Local Anesthetics vii. Market Forecast c. Combined Market Forecast ii. Pain Management Devices a. Electrical Stimulators i. Transcutaneous Electrical Nerve Stimulators ii. Neurostimulators iii. Market Forecast b. Analgesia Infusion Pumps i. Implantable Analgesia Infusion Pumps ii. External Analgesia Infusion Pumps iii. Market Forecast c. Combined Market Forecast iii. Combined Market Forecast Exhibit ES-1: Nonprescription Analgesics/Anesthetics, Market Share, by Product Segment, 2013 and 2018 Exhibit ES-2: Prescription Analgesics/Anesthetics, Market Share, by Product Segment, 2013 and 2018 Exhibit ES-3: Pain Management Pharmaceuticals, Combined Market Share, by Product Segment, 2013 and 2018 Exhibit ES-4: Electrical Stimulators, Market Share, by Product Segment, 2013 and 2018 Exhibit ES-5: Analgesia Infusion Pumps, Market Share, by Product Segment, 2013 and 2018 Exhibit ES-6: Pain Management Devices, Combined Market Share, by Product Segment, 2013 and 2018 Exhibit ES-7: Pain Management Pharmaceuticals and Devices, Combined Market Share, by Product Segment, 2013 and 2018 1. PAIN MANAGEMENT OVERVIEW 1.1 Pain Physiology 1.1.1 The Nervous System 1.1.2 Pain Perception 1.1.3 Pain Classification 220.127.116.11 Nociceptive Pain 18.104.22.168 Non-Nociceptive Pain 22.214.171.124 Acute Pain 126.96.36.199 Chronic Pain 1.2 Pain Assessment Techniques 1.3 Pain Prevalence 1.4 Common Pain Syndromes 1.4.1 Arthritis Pain 1.4.2 Back Pain 1.4.3 Burn Pain 1.4.4 Cancer Pain 1.4.5 Headache Pain 1.4.6 Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome Pain 1.4.7 Obstetric Pain 1.4.8 Podiatric Pain 1.4.9 Sciatic Pain 1.4.10 Temporomandibular Pain 1.4.11 Trauma Pain 1.5 Clinical Approaches to Pain Management 1.5.1 Pain Management Guidelines 1.5.2 Pain Management Guidelines for Older Adults 1.5.3 Interventional Pain Management Guidelines 1.5.4 Pain Management Options 188.8.131.52 Pharmaceutical Options 184.108.40.206 Device-Based Options 220.127.116.11 Alternative Therapy Options Exhibit 1-1: Common Causes of Neuropathic Pain Exhibit 1-2: United States Population, by Selected Ages, 1990-2050 Exhibit 1-3: Overview of the Joint Commission's Standards for Pain Assessment and Management 2. PAIN MANAGEMENT PHARMACEUTICALS 2.1 Pharmaceutical Formulations and Drug Delivery 2.1.1 Oral Drug Delivery 2.1.2 Injection/Infusion Drug Delivery 18.104.22.168 Injection 22.214.171.124.1 Intramuscular Injection 126.96.36.199.2 Subcutaneous Injection 188.8.131.52 Infusion 184.108.40.206.1 Intravenous Infusion 220.127.116.11.2 Intraspinal Infusion 18.104.22.168.3 Intraoperative Site Infusion 2.1.3 Inhalation Drug Delivery 2.1.4 Transdermal Drug Delivery 2.1.5 Transmucosal Drug Delivery 2.1.6 Nonsteroidal Anti-Inflammatory Drugs 22.214.171.124 Heart Attack and Hypertension Risks 126.96.36.199 The Food and Drug Administration and Labeling 188.8.131.52 Naproxen Risks 2.2 The Benefits of Aspirin 2.2.1 Aspirin and Heart Attack/Stroke Prevention 2.2.2 Aspirin and Heart Failure 2.2.3 Aspirin and Cancer Prevention 2.3 Market Analysis 2.3.1 Nonprescription Analgesics and Anesthetics 184.108.40.206 Market Forecast 220.127.116.11 Nonprescription Systemic Analgesics 18.104.22.168.1 Acetaminophen 22.214.171.124.2 Nonprescription Nonsteroidal Anti-Inflammatory Drugs 126.96.36.199.3 Market Forecast 188.8.131.52.4 Competitive Analysis 184.108.40.206 Nonprescription Topical Analgesics and Anesthetics 220.127.116.11.1 Amino Amides and Esters 18.104.22.168.2 Capsaicin 22.214.171.124.3 Methyl and Trolamine Salicylates 126.96.36.199.4 Topical Patches 188.8.131.52.5 Market Forecast 184.108.40.206.6 Competitive Analysis 2.3.2 Prescription Analgesics and Anesthetics 220.127.116.11 Market Forecast 18.104.22.168 Prescription Nonsteroidal Anti-Inflammatory Drugs 22.214.171.124.1 Acetic Acid Derivatives 126.96.36.199.2 Anthranilic Acid Derivatives 188.8.131.52.3 Cyclooxygenase-2 Selective Inhibitors 184.108.40.206.4 Enolic Acid Derivatives 220.127.116.11.5 Propionic Acid Derivatives 18.104.22.168.6 Salicylic Acid Derivatives 22.214.171.124.7 Market Forecast 126.96.36.199.8 Competitive Analysis 188.8.131.52 Opioid Analgesics 184.108.40.206.1 Buprenorphine 220.127.116.11.2 Butorphanol 18.104.22.168.3 Codeine 22.214.171.124.4 Fentanyl 126.96.36.199.5 Hydromorphone 188.8.131.52.6 Levorphanol 184.108.40.206.7 Meperidine 220.127.116.11.8 Morphine 18.104.22.168.9 Nalbuphine 22.214.171.124.10 Oxycodone 126.96.36.199.11 Oxymorphone 188.8.131.52.12 Pentazocine 184.108.40.206.13 Propoxyphene 220.127.116.11.14 Remifentanil 18.104.22.168.15 Tramadol 22.214.171.124.16 Tapentadol 126.96.36.199.17 Hydrocodone 188.8.131.52.18 Market Forecast 184.108.40.206.19 Competitive Analysis 220.127.116.11 Opioid/Nonopioid Combination Analgesics 18.104.22.168.1 Market Forecast 22.214.171.124.2 Competitive Analysis 126.96.36.199 Antimigraine Analgesics 188.8.131.52.1 Diclofenac 184.108.40.206.2 Dihydroergotamine 220.127.116.11.3 Divalproex Sodium 18.104.22.168.4 Triptans 22.214.171.124.5 Market Forecast 126.96.36.199.6 Competitive Analysis 188.8.131.52 Adjuvant Analgesics 184.108.40.206.1 Anticonvulsants 220.127.116.11.2 Antidepressants 18.104.22.168.3 Corticosteriods 22.214.171.124.4 Market Forecast 126.96.36.199.5 Competitive Analysis 188.8.131.52 General, Regional, and Local Anesthetics 184.108.40.206.1 Inhalation General Anesthetics 220.127.116.11.2 Intravenous General Anesthetics 18.104.22.168.3 Anesthetics Used in Balanced Anesthesia 22.214.171.124.4 Regional/Local Anesthetics 126.96.36.199.5 Market Forecast 188.8.131.52.6 Competitive Analysis 2.3.3 Combined Market Forecast Exhibit 2-1: Advantages and Disadvantages of Common Drug Delivery Methods Exhibit 2-2: 2014, Selected Nonprescription Analgesics and Anesthetics Exhibit 2-3: 2014, Selected Prescription Analgesics and Anesthetics Exhibit 2-4: Nonprescription Analgesics and Anesthetics, Market Forecast 2013-2018 Exhibit 2-5: Nonprescription Systemic Analgesics, Market Forecast, 2013-2018 Exhibit 2-6: 2013, Nonprescription Systemic Analgesics Market, Share by Supplier Exhibit 2-7: Nonprescription Topical Analgesics/Anesthetics, Market Forecast, 2013-2018 Exhibit 2-8: 2013, Nonprescription Topical Analgesics/Anesthetics Market, Share by Supplier Exhibit 2-9: Prescription Analgesics and Anesthetics, Market Forecast, 2013-2018 Exhibit 2-10: Prescription Nonsteroidal Anti-Inflammatory Drugs, Market Forecast, 2013-2018 Exhibit 2-11: 2013, Prescription Nonsteroidal Anti-Inflammatory Drugs Market, Share by Supplier Exhibit 2-12: Prescription Opioid Analgesics, Market Forecast, 2013-2018 Exhibit 2-13: 2013, Prescription Opioid Analgesics Market, Share by Supplier Exhibit 2-14: Prescription Opioid/Nonopioid Combination Analgesics, Market Forecast, 2013-2018 Exhibit 2-15: Prescription Antimigraine Analgesics, Market Forecast, 2013-2018 Exhibit 2-16: 2013, Prescription Antimigraine Analgesics Market, Share by Supplier Exhibit 2-17: Prescription Adjuvant Analgesics, Market Forecast, 2013-2018 Exhibit 2-18: 2013, Prescription Adjuvant Analgesics Market, Share by Supplier Exhibit 2-19: General, Regional, and Local Anesthetics, Market Forecast, 2013-2018 Exhibit 2-20: 2013, General, Regional, and Local Anesthetics Market, Share by Supplier Exhibit 2-21: Pain Management Pharmaceuticals, Combined Market Forecast, 2013-2018 3. PAIN MANAGEMENT DEVICES 3.1 Electrical Stimulators 3.1.1 Transcutaneous Electrical Nerve Stimulators 184.108.40.206 Market Forecast 220.127.116.11 Competitive Analysis 3.1.2 Neurostimulators 18.104.22.168 Occipital Nerve Stimulation 22.214.171.124 Neuromuscular Stimulators 126.96.36.199 Spinal Cord and Peripheral Nerve Stimulators 188.8.131.52 Market Forecast 184.108.40.206 Competitive Analysis 3.2 Analgesia Infusion Pumps 3.2.1 Implantable Analgesia Infusion Pumps 220.127.116.11 Market Forecast 18.104.22.168 Competitive Analysis 3.2.2 External Analgesia Infusion Pumps 22.214.171.124 Nerve Block 126.96.36.199 Patient-Controlled Analgesia Infusion Pumps 188.8.131.52 Products 184.108.40.206 Market Forecast 220.127.116.11 Competitive Analysis 3.3 Combined Market Forecast Exhibit 3-1: Proposed Fourth Step of the World Health Organization Analgesic Ladder Exhibit 3-2: Selected Painful Conditions Appropriate for Electrical Stimulation Therapy Exhibit 3-3: Transcutaneous Electrical Nerve Stimulators, Market Forecast, 2013-2018 Exhibit 3-4: 2013, Transcutaneous Electrical Nerve Stimulators Market, Share by Supplier Exhibit 3-5: Neurostimulators, Market Forecast, 2013-2018 Exhibit 3-6: 2013, Spinal Cord Stimulators Market, Share by Supplier Exhibit 3-7: 2013, Neuromuscular Stimulators Market, Share by Supplier Exhibit 3-8: Implantable Analgesia Infusion Pumps, Market Forecast, 2013-2018 Exhibit 3-9: 2013, Implantable Analgesia Infusion Pumps Market, Share by Supplier Exhibit 3-10: External Analgesia Infusion Pumps, Market Forecast, 2013-2018 Exhibit 3-11: 2013, External Analgesia Infusion Pumps Market, Share by Supplier Exhibit 3-12: Pain Management Devices, Combined Market Forecast, 2013-2018 4. COMPANY PROFILES 4.1 AstraZeneca PLC 4.2 Baxter Healthcare, Inc./Baxter International, Inc. 4.3 Bayer HealthCare AG/Bayer AG 4.4 Boston Scientific Corporation 4.5 CareFusion Corporation 4.6 Chattem, Inc./sanofi-aventis LLC 4.7 DJO Global, Inc. 4.8 Eli Lilly and Company 4.9 Endo Pharmaceutical Holdings, Inc./Endo International PLC 4.10 GlaxoSmithKline PLC 4.11 Hospira, Inc. 4.12 International Rehabilitative Sciences, Inc., d/b/a RS Medical 4.13 Johnson & Johnson 4.14 Medtronic, Inc. 4.15 Pfizer, Inc. 4.16 Purdue Pharma LP 4.17 Teva Pharmaceutical Industries LTD APPENDIX: COMPANY LISTING